ArticleJCI insight2020
Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer.
Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint.Clinical epigenetics · 2021Trial
- Clinical translation of an immunomodulatory cell therapy that is designed to convert "cold" tumors to "hot": A phase 2B trial in 3L MSS/pMMR metastatic colorectal cancer.Translational oncology · 2026Article
- Vaccine Therapy for the Management of Penile Cancer: Evidence, Opportunities and Challenges.Vaccines · 2026Review
- Epigenetic orchestration of cancer-immune dynamics: mechanisms, technologies, and clinical advancements.Journal of advanced research · 2026Review
- DNA, RNA, and histone methylation regulation enzymes and their crosstalk in colorectal carcinogenesis and progression: a review of molecular mechanisms, clinical implications, and future perspectives.Cellular & molecular biology letters · 2025Review
- Recent advances and challenges in colorectal cancer: From molecular research to treatment.World journal of gastroenterology · 2025Review
- Signature Gene Mutations in Colorectal Cancer: Potential Neoantigens for Cancer Vaccines.International journal of molecular sciences · 2025Review
- Tumor-infiltrating immune cell signature score reveals prognostic biomarkers and therapeutic targets for colorectal cancer.Frontiers in immunology · 2025Article
- Article
- Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics.British journal of cancer · 2023Review
- Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison.Bioactive materials · 2023Review
- Improvement in neoantigen prediction via integration of RNA sequencing data for variant calling.Frontiers in immunology · 2023Article
- Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers.Frontiers in immunology · 2023Review
- Neoantigens and their clinical applications in human gastrointestinal cancers.World journal of surgical oncology · 2022Review
- Engineered implantable vaccine platform for continuous antigen-specific immunomodulation.Biomaterials · 2022Article
- Colorectal cancer vaccines: The current scenario and future prospects.Frontiers in immunology · 2022Review
- Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.Disease markers · 2022Review
- Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in glioma.Frontiers in oncology · 2022Article
- Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.Biomaterials · 2022Review
- Allogeneic tumor cell line-based vaccines: A good alternative to autologous and cancer stem cell vaccines in colorectal cancer.Iranian journal of basic medical sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Metastatic colorectal cancer (CRC) is poorly immunogenic, with limited neoantigens that can be targeted by cancer vaccine. Previous approaches to upregulate neoantigen have had limited success. In this study, we investigated the role of a DNA methyltransferase inhibitor (DNMTi), 5-aza-2'-deoxycytidine (DAC), in inducing cancer testis antigen (CTA) expression and evaluated the antitumor efficacy of a combinatorial approach with an epigenetically regulated cancer vaccine EpiGVAX and DAC. A murine model of metastatic CRC treated with combination therapy with an irradiated whole-cell CRC vaccine (GVAX) and DAC was used to assess the antitumor efficacy. DAC significantly induced expression of CTAs in CRC, including a new CTA Tra-P1A with a known neoepitope, P1A. Epigenetically modified EpiGVAX with DAC improved survival outcomes of GVAX. Using the epigenetically regulated antigen Tra-P1A as an example, our study suggests that the improved efficacy of EpiGVAX with DAC may due in part to the enhanced antigen-specific antitumor immune responses. This study shows that epigenetic therapy with DNMTi can not only induce new CTA expression but may also sensitize tumor cells for immunotherapy. Neoantigen-based EpiGVAX combined with DAC can improve the antitumor efficacy of GVAX by inducing antigen-specific antitumor T cell responses to epigenetically regulated proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.